Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Simon Planken(Pfizer (United States)), Jennifer Lafontaine(Pfizer (United States)), Scott L. Weinrich(Pfizer (United States)), Sajiv K. Nair(Pfizer (United States)), K.S. Gajiwala(Pfizer (United States)), Brion W. Murray(Pfizer (United States)), Louise Bernier(Pfizer (United States)), John C. Kath(Pfizer (United States)), Michael Zientek(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Khanh Tran(Pfizer (United States)), Shuibo Xin(WuXi AppTec (China)), Chau Almaden(Pfizer (United States)), Hengmiao Cheng(Pfizer (United States)), Hong Shen(University of Michigan), Judith G. Deal(Pfizer (United States)), Deepak Dalvie(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Jean Matthews(Pfizer (United States)), Theodore Johnson(Pfizer (United States)), Elaine Tseng(University of California, San Francisco), Neal W. Sach(Pfizer (United States)), Rose Ann Ferre(Pfizer (United States)), Simon Bailey(The University of Melbourne), Asako Nagata(Pfizer (United States)), James Solowiej(Pfizer (United States)), Longqing Liu(WuXi AppTec (China)), Sujin Cho-Schultz(Pfizer (United States)), Suvi T. M. Orr(Tracon Pharmaceuticals (United States)), Sherry Niessen(Pfizer (United States)), T. Eric Ballard(Pfizer (United States)), Douglas C. Behenna(Pfizer (United States)), Mason Pairish(Pfizer (United States)), Yuli Wang(Pfizer (United States)), Yiqin Luo(Anhui Provincial Hospital), Chengyi Zhang(Wuhan University of Science and Technology), Manli Shi(Pfizer (United States)), Paolo Vicini(Pfizer (United States)), Dac M. Dinh(Pfizer (United States)), Ru Zhou(University of British Columbia), Michelle Hemkens(Pfizer (United States))
Journal of Medicinal Chemistry
March 13, 2017
10.1021/acs.jmedchem.6b01894
Cited by 90

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382
Lipophilic Efficiency as an Important Metric in Drug Design
|Journal of Medicinal Chemistry|2018|340